Jeremy Bender, Day One CEO

Day One to file NDA for pe­di­atric brain can­cer drug by sum­mer

Day One Bio­phar­ma­ceu­ti­cals will ask reg­u­la­tors to ap­prove its pe­di­atric brain can­cer drug tovo­rafenib be­fore the sec­ond half of 2023, the biotech said Sun­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.